South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major ...

Eli Lilly has signed an agreement with ABL Biotech for access to the South Korean biotech's Grabody platform to develop ...

ABL Bio has unveiled a strategy to expand its bispecific antibody platform technology, which has been focused on brain ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. | Neok Bio has exited stealth with $75 million to take a pair ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...

SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or ...

Hana Securities stated that the selection of new stocks to be added to the MSCI index in February next year is highly likely to be determined by ...

SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative ...

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...